title: Pancreas preservation with University of Wisconsin and Celsior solutions: a single-center, prospective, randomized pilot study.
abstract: BACKGROUND
  Celsior is an extracellular-type, low-viscosity, preservation solution already used for heart, lung, liver, and kidney transplantation. We report the results of a single-center, prospective, randomized pilot study specifically designed to compare the safety profile of Celsior solution with University of Wisconsin (UW) solution in clinical pancreas transplantation.
  
  
  METHODS
  A total of 105 consecutive procurements were randomized to graft preservation with UW (n=53) solution or Celsior (n=52) solution. The groups were comparable with regard to all donor and recipient characteristics.
  
  
  RESULTS
  Five grafts were discarded and 100 grafts (50 UW vs. 50 Celsior) were transplanted. Mean cold and warm ischemia times were 11.0 +/- 2.1 hr and 37.2 +/- 6.0 min for UW compared with 10.8 +/- 1.8 hr and 38.1 +/- 5.9 min for Celsior (P =not significant). Delayed endocrine pancreas function was recorded in one graft preserved with UW solution. Eleven recipients (UW 12% vs. Celsior 10%, P =not significant) required a relaparotomy. The mean serum levels of glucose, amylase, and lipase remained comparable between the study arms at equivalent intervals after transplantation. One recipient died with functioning grafts in each study arm; two further grafts were lost to arterial thrombosis (Celsior) and chronic rejection (UW), respectively. Actuarial 1-year patient and graft survival rates overlapped in the two study arms (98% and 96%, respectively).
  
  
  CONCLUSIONS
  Within the range of cold ischemia time reported in this study, UW and Celsior solutions have similar safety profiles for pancreas preservation.
authors.affiliation: Divisione di Chirurgia Generale e Trapianti, Dipartimento di Oncologia, Trapianti e Nuove Tecnologie in Medicina, Università di Pisa, Pisa, Italy. u.boggi@med.unipi.it
authors.forename: Ugo
authors.initials: U
authors.lastname: Boggi
authors.forename: Fabio
authors.initials: F
authors.lastname: Vistoli
authors.forename: Marco
authors.initials: M
authors.lastname: Del Chiaro
authors.forename: Stefano
authors.initials: S
authors.lastname: Signori
authors.forename: Chiara
authors.initials: C
authors.lastname: Croce
authors.forename: Andrea
authors.initials: A
authors.lastname: Pietrabissa
authors.forename: Raffaella
authors.initials: R
authors.lastname: Berchiolli
authors.forename: Piero
authors.initials: P
authors.lastname: Marchetti
authors.forename: Stefano
authors.initials: S
authors.lastname: Del Prato
authors.forename: Franco
authors.initials: F
authors.lastname: Mosca
mesh_terms: D000241:Adenosine; D000328:Adult; D000493:Allopurinol; D004187:Disaccharides; D004573:Electrolytes; D005260:Female; D005971:Glutamates; D005978:Glutathione; D006639:Histidine; D006801:Humans; D066298:In Vitro Techniques; D007328:Insulin; D008297:Male; D008353:Mannitol; D008875:Middle Aged; D009926:Organ Preservation / Q000191:economics / Q000379:methods*; D019188:Organ Preservation Solutions; D010179:Pancreas; D016035:Pancreas Transplantation; D010865:Pilot Projects; D011446:Prospective Studies; D011887:Raffinose; D012449:Safety; D014019:Tissue Donors
chemical_list: C088453:Celsior; D004187:Disaccharides; D004573:Electrolytes; D005971:Glutamates; D007328:Insulin; D019188:Organ Preservation Solutions; C055206:University of Wisconsin-lactobionate solution; D008353:Mannitol; D006639:Histidine; D000493:Allopurinol; D005978:Glutathione; D000241:Adenosine; D011887:Raffinose